Drugs / p55gag
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03181789 | Oct 2017 → Oct 2019 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04357821 | Aug 2020 → Jun 2026 overdue | HIV infectious disease | University of California, San Francisco | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | p55gag | “IL-12 adjuvanted DNA boost (p24CE plus p55gag)” NCT04357821 ↗ |
| Known as | p55^gag pDNA Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03181789 ↗ |
| Modality | Vaccine | “two HIV-1 pDNA vaccines” NCT03181789 ↗ |
| Route | Intramuscular | “given by intramuscular (IM) injection with electroporation (EP)” NCT03181789 ↗ |